Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ossama A Ahmed, Mohamed A Elsebaey, Mohamed Hassan A Fouad, Heba Elashry, Ahmed I Elshafie, Ahmed A Elhadidy, Noha E Esheba, Mohammed H Elnaggar, Shaimaa Soliman & Sherief Abd-Elsalam. (2018) Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infection and Drug Resistance 11, pages 441-445.
Read now
Read now
Young-Mo Yang & Eun Joo Choi. (2017) Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Therapeutics and Clinical Risk Management 13, pages 477-497.
Read now
Read now
Aisha Elsharkawy, Rasha Eletreby, Rabab Fouad, Zeinab Soliman, Mohamed Abdallah, Mohamed Negm, Mohammad Mohey & Gamal Esmat. (2017) Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Review of Gastroenterology & Hepatology 11:8, pages 773-778.
Read now
Read now
Yan A. Ivanenkov, Vladimir A. Aladinskiy, Nikolay A. Bushkov, Andrey A. Ayginin, Alexander G. Majouga & Alexandre V. Ivachtchenko. (2017) Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opinion on Therapeutic Patents 27:4, pages 401-414.
Read now
Read now
Articles from other publishers (34)
Ahmed H. Moustafa, Heba F. Pasha, Manar A. Abas & Adel M. Aboregela. (2022) The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats. Anatomy & Cell Biology 56:1, pages 109-121.
Crossref
Crossref
Jitender Monga, Frederick Valeriote, Clara Hwang, Shirish Gadgeel & Jagadananda Ghosh. (2023) Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics 22:3, pages 381-392.
Crossref
Crossref
Trung Cao, Natalia Dyatkina, Sébastien Lemaire, Marija Prhavc & Simon Wagschal. 2022. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry. Volume 4. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry. Volume 4
95
141
.
HanyMohammed Ibrahim, FatenRoshdy Abdel-Ghaffar, AhmedBahgat Zied & SamehaHusni El-Ghareeb. (2022) Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome. Biomedical and Biotechnology Research Journal (BBRJ) 6:1, pages 109.
Crossref
Crossref
Jessica Markby, Sonjelle Shilton, Xiaohui Sem, Huan Keat Chan, Rosaida Md Said, Sasikala Siva, Zalwani Zainuddin, Norasiah Abu Bakar, Haniza Omar, Ryan Jose III Ruiz, Mary Gaeddert, Alexander Tyshkovskiy, Madeline Adee, Jagpreet Chhatwal, Suresh Kumar, Jean-Michel Piedagnel, Rozainanee Mohd Zain, Caroline Menétrey, Fazidah Yuswan, Nazrila Hairizan Nasir, Isabelle Andrieux-Meyer, Fatanah Ismail, Rozita Zakaria, Ruziaton Hasim, Shahnaz Murad, Philippa Easterbrook & Muhammad Radzi Abu Hassan. (2021) Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study. BMJ Open 11:12, pages e055142.
Crossref
Crossref
Sherif Abbass, Ehab Kamal, Mohsen Salama, Tary Salman, Alyaa Sabry, Wael Abdel‐Razek, Sherine Helmy, Ahmed Abdelgwad, Neamt Sakr, Mohamed Elgazzar, Mohamed Einar, Mahmoud Farouk, Mounir Saif, Ismail Shehab, Eman El‐hosieny, Mai Mansour, Doaa Mahdi, El‐Sayed Tharwa, Mostafa Salah, Ola Elrouby & Imam Waked. (2021) Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID‐19: A randomized controlled trial. Journal of Medical Virology 93:12, pages 6750-6759.
Crossref
Crossref
Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song & Mong Cho. (2021) Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. Gut and Liver 15:3, pages 440-450.
Crossref
Crossref
Deepthi Ramesh, Balaji Gowrivel Vijayakumar & Tharanikkarasu Kannan. (2021) Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections. ChemMedChem 16:9, pages 1403-1419.
Crossref
Crossref
Hanxiao Yu, He Yang, Enxue Shi & Wenjun Tang. (2020) Development and Clinical Application of Phosphorus-Containing Drugs. Medicine in Drug Discovery 8, pages 100063.
Crossref
Crossref
Andrey V. Smolobochkin, Rakhymzhan A. Turmanov, Almir S. Gazizov, Elizaveta A. Kuznetsova, Alexander R. Burilov & Mikhail A. Pudovik. (2020) Synthesis of Novel 2-Hetarylpyrrolidines via the Reaction of N-(4,4-diethoxybutyl)amidophosphates with C-nucleophiles. Chemistry of Heterocyclic Compounds 56:10, pages 1363-1365.
Crossref
Crossref
Hany M. Elsadek, Elsayed S. Abdelbaser, Mohamed H. Emara, Hanan H. Soliman & Alaa A. Farag. (2020) Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. European Journal of Gastroenterology & Hepatology 32:8, pages 1046-1053.
Crossref
Crossref
Marc Montana, Vincent Montero, Omar Khoumeri & Patrice Vanelle. (2020) Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. Molecules 25:12, pages 2784.
Crossref
Crossref
Ahmed Nagaty, Sherine H A Helmy & Ekram W Abd El-Wahab. (2020) Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Transactions of The Royal Society of Tropical Medicine and Hygiene 114:3, pages 200-212.
Crossref
Crossref
Lamiaa N. Abdelaty, Ahmed A. Elnaggar, Amira A. Said & Raghda R.S. Hussein. (2020) Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Current Drug Safety 15:1, pages 53-60.
Crossref
Crossref
Satish Kumar, P.K. Santra, J. Dwivedi & R.C. Aryan. (2020) Synthesis, Characterization and Docking Studies of Anti-HCV Molecules. Asian Journal of Chemistry 32:5, pages 1221-1229.
Crossref
Crossref
Jenny Jeehan Nasr & Shereen Shalan. (2020) Validated 1H and 19F nuclear magnetic resonance for the quantitative determination of the hepatitis C antiviral drugs sofosbuvir, ledipasvir, and daclatasvir in tablet dosage forms. Microchemical Journal 152, pages 104437.
Crossref
Crossref
Maha Mahmoud Abou El-Alamin, Maha Abd Elrahman Sultan, Maha Hegazy, Alastair William Wark & Marwa Mohamed Azab. (2019) Pure component contribution (PCCA) and synergy interval partial least squares (siPLS) algorithms for efficient resolution and quantification of overlapped signals; an application to novel antiviral tablets of daclatasvir, sofosbuvir and ribavirin. European Journal of Chemistry 10:4, pages 350-357.
Crossref
Crossref
Naomi Khaing Than Hlaing, Gayatri Nangia, Kyaw Thet Tun, Sithu Lin, Moe Zaw Maung, Khin Thuzar Myint, A. Mi Mi Kyaw, Soe Thiha Maung, Sithu Sein Win, Aung Hlaing Bwa, Bao‐Li Loza, Khin Maung Win & K. Rajender Reddy. (2019) High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. Journal of Viral Hepatitis 26:10, pages 1186-1199.
Crossref
Crossref
Aya A Youssef, N Magdy, Lobna A Hussein & A M El-Kosasy. (2019) Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt. Journal of Chromatographic Science 57:7, pages 636-643.
Crossref
Crossref
Guangyi Wang, Natalia Dyatkina, Marija Prhavc, Caroline Williams, Vladimir Serebryany, Yujian Hu, Yongfei Huang, Jinqiao Wan, Xiangyang Wu, Jerome Deval, Amy Fung, Zhinan Jin, Hua Tan, Kenneth Shaw, Hyunsoon Kang, Qingling Zhang, Yuen Tam, Antitsa Stoycheva, Andreas Jekle, David B. Smith & Leonid Beigelman. (2019)
Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′-
C
-methyluridine 5′-Phosphoramidate Prodrug (
AL-335
) for the Treatment of Hepatitis C Infection
. Journal of Medicinal Chemistry 62:9, pages 4555-4570.
Crossref
Crossref
Tawhida Y. Abdel Ghaffar, Suzan El Naghi, Manal Abdel Gawad, Sarah Helmy, Aisha Abdel Ghaffar, Medhat Yousef & Mohamad Moafy. (2019) Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. Journal of Viral Hepatitis 26:2, pages 263-270.
Crossref
Crossref
E. A. Nurmukhametova, N. P. Blokhina & S. V. Smetanina. (2019) Organization of medical care and drug provision for patients with chronic hepatitis C in Moscow. Dokazatel'naya gastroenterologiya 8:1, pages 84.
Crossref
Crossref
Rodolfo Perez-Alamino. 2019. Infections and the Rheumatic Diseases. Infections and the Rheumatic Diseases
107
112
.
Monjur Ahmed. (2018) Era of direct acting anti-viral agents for the treatment of hepatitis C. World Journal of Hepatology 10:10, pages 670-684.
Crossref
Crossref
Ewelina Krol, Gabriela Pastuch-Gawolek, Binay Chaubey, Gabriela Brzuska, Karol Erfurt & Boguslaw Szewczyk. (2018) Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds. Molecules 23:6, pages 1435.
Crossref
Crossref
Varun Mehta, Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez & Ajit Sood. (2018) Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India. Journal of Clinical and Experimental Hepatology 8:1, pages 7-14.
Crossref
Crossref
Ossama Ashraf Ahmed, Eslam Safwat, Mohamed Omar Khalifa, Ahmed I. Elshafie, Mohamed Hassan Ahmed Fouad, Mohamed Magdy Salama, Gina Gamal Naguib, Mohamed Mahmoud Eltabbakh, Ahmed Fouad Sherief & Sherief Abd-Elsalam. (2018) Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. International Journal of Hepatology 2018, pages 1-5.
Crossref
Crossref
Ludmila Maistat, Natalija Kravchenko & Amulya Reddy. (2017) Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries. Hepatology, Medicine and Policy 2:1.
Crossref
Crossref
Elena Ivanova Reipold, Philippa Easterbrook, Alessandra Trianni, Nivedha Panneer, Douglas Krakower, Stefano Ongarello, Teri Roberts, Veronica Miller & Claudia Denkinger. (2017) Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile. BMC Infectious Diseases 17:S1.
Crossref
Crossref
Rob Bielen, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixko, Jochen Decaestecker, Chantal De Galocsy, Filip Janssens, Mike Cool, Lode Van Overbeke, Christophe Van Steenkiste, François D'heygere, Wilfried Cools, Frederik Nevens & Geert Robaeys. (2017) Belgian experience with direct acting antivirals in people who inject drugs. Drug and Alcohol Dependence 177, pages 214-220.
Crossref
Crossref
Patrice Cacoub, Cloé Comarmond, Anne Claire Desbois & David Saadoun. (2017) Rheumatologic Manifestations of Hepatitis C Virus Infection. Clinics in Liver Disease 21:3, pages 455-464.
Crossref
Crossref
Ying-Hong Li, Zhou-Yi Wu, Sheng Tang, Xin Zhang, Yan-Xiang Wang, Jian-Dong Jiang, Zong-Gen Peng & Dan-Qing Song. (2017) Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton. Bioorganic & Medicinal Chemistry Letters 27:9, pages 1962-1966.
Crossref
Crossref
Patrice Cacoub, Cloé Commarmond, David Sadoun & Anne Claire Desbois. (2017) Hepatitis C Virus Infection and Rheumatic Diseases. Rheumatic Disease Clinics of North America 43:1, pages 123-132.
Crossref
Crossref
Shahin Merat, Amir Houshang Sharifi, Arghavan Haj-Sheykholeslami, Hossein Poustchi, Babak Fattahi, Alireza Nateghi-Baygi, Seyed Moayed Alavian & Reza Malekzadeh. (2016) The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepatitis Monthly 17:1.
Crossref
Crossref